Marvel Biosciences Corp · TSXV:MRVL
Marvel Biosciences — Investor Presentation (December 2024)
19 slides from Marvel Biosciences's investor presentation, December 2024
Slide 1: Corporate Presentation Dec 2024
Corporate Presentation Dec 2024 MRVL–TSXV MBCOF-OTC www.marvelbiotechnology.com 1
Slide 2: Disclaimer
Disclaimer Forward-Looking Information and Statements This presentation contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than s
Slide 3: Executive Summary
Executive Summary • Marvel has developed MB-204, a novel patented inhibitor of the A2a receptor for neurological disorders, led by Dr. Mark Williams who has successfully redeveloped two prior compounds • Exceptional immediate efficacy in autism (Rett) and depression from third party animal experimen
Slide 4: Problem: Autism, Depression & Alzheimer's Disease Remain Undertreated
Problem: Autism, Depression & Alzheimer’s Disease Remain Undertreated Autism Depression Alzheimer’s Successfully Redeveloped Drugs 1 in 36 children affected1 1 in 8 adults takes an anti-depressant4 1 in 10 persons over 65 affected6 $450B est social cost in 20252 $330B est in US alone for economic bu
Slide 5: Autism Spectrum Disorder: Specific conditions and treatments
Autism Spectrum Disorder: Specific conditions and treatments Rett Syndrome Fragile X Daybue (Trofinetide) Zatolmilast (Phase 3) #patients: 6,000-9,000 in USA1 #patients: >100,000 in USA3 Only FDA approved drug (2023) No approved treatments Est. 2024 Net sales: Symptomatic relief only US$370-420 mill
Slide 6: Deal Economics of the Two Leading Compounds
Deal Economics of the Two Leading Compounds Preclinical Phase 1 Phase 2 Phase 3/ Commercial Neuren Pharmaceuticals (Rett/FXS) Rett Syndrome: Acadia Pharmaceutical 2018: $10M Milestones: $50M Royalties: $0.35B • Deal NPV of ~US$120M • Daybue was in Phase 2 trials at the time of the deal Tetra Therape
Slide 7: Solution: Marvel Redeveloped an Approved Drug for A Well-Known Target
Solution: Marvel Redeveloped an Approved Drug for A Well-Known Target Istradefylline Activates Dopamine D2 MB-204 Approved for Parkinson’s Socialization - Autism Patented Istradefylline Analog Third Party Science Motivation - Depression De-Risked Asset Off-Patent Memory – Alzheimer’s Strong Preclini
Slide 8: MB-204 - Immediate Effect on Autism in Rett Syndrome Model
MB-204 - Immediate Effect on Autism in Rett Syndrome Model Rett Syndrome Collaboration funded by the iBraiN Institute and testing conducting by experts in the field Conducted studies on MB-204 in a Knockout Autism Model, observing significant improvements in sociability and reductions in repetitive
Slide 9: Short Term Catalysts
Short Term Catalysts Q1:2025 Q3:2025 Q1:2026 Mouse Alzheimer’s study Phase 1 Multiple Dose clinical trial Complete Rett Syndrome and results of MB-204 Fragile X Mouse studies Single Dose Phase 1 – safety and POC efficacy results Accelerate partnership talks or Phase 1 start possible NASDAQ listing M
Slide 10: Collaboration to Test MB-204 in Fragile X Models
Collaboration to Test MB-204 in Fragile X Models Fragile X Syndrome Collaboration funded by FRAXA Starting in Q4 2024, FRAXA will be preclinically testing MB-204 in a Fragile X Syndrome (FXS) model 1 in 7000 males / 11,000 females Fmr1 gene mutation (orphan) MB-204 has previously shown effectiveness
Slide 11: Collaboration to Test MB-204 in Alzheimer's Tau Models
Collaboration to Test MB-204 in Alzheimer’s Tau Models Partnership with Dr. Planel Grant to Test MB-204 in Alzheimer’s Disease MB-204 reduced tau hyperphosphorylation, a 3-month 2 dose study in 5xFAD mice (starting at 6 key marker of Alzheimer’s disease, in an acute in months of age) vivo study • Co
Slide 12: IND-Enabling Toxicology and Manufacturing Completed – Clinic Ready
IND*-Enabling Toxicology and Manufacturing Completed – Clinic Ready 4-week GLP** toxicology in rats and beagle dogs completed & No Adverse Events Levels (NOAEL) determined: 150 mg/kg/day 10 mg/kg/day • Genotoxicity studies completed – no issues • cGMP*** active pharmaceutical ingredient (API) ready
Slide 13: Overall Long-Term Strategic Plan
Overall Long-Term Strategic Plan 13
Slide 14: Marvel Biosciences Investment Opportunity
Marvel Biosciences Investment Opportunity Canadian-Based Biotechnology Mission Company Information • Lean enterprise Ticker: MRVL, MBCOF • Led by Science and Quality focused(3rd party studies) Exchange: TSXV, OTC Headquarters: Calgary, Alberta, Canada Major Milestones Shares Outstanding: 44.8 millio
Slide 15: Management
Management J. Roderick Matheson Dr. Mark Williams HarryNijjar - CPA, CMA Chief Executive Officer and Director President, Chief Science Officer and Director Chief Financial Officer Mr. Matheson has spent nearly 40 years of his career in the investment and Mark Williams is currently the CSO and Presid
Slide 16: Board of Directors
Board of Directors Neil A. Johnson – Director Mr. Johnson has over 30 years of experience in investment banking, merchant banking and research analysis in both the Canadian and UK capital markets. Mr. Johnson is presently, and has been since June 2015, Executive Director and Chief Executive Officer
Slide 17: Scientific Advisory Board
Scientific Advisory Board Dr. David Blum Dr. Blum adds crucial depth to the scientific board for his highly relevant research in the A2A receptor antagonists in cognition, brain lesions, and tau pathology for applications in Alzheimer's Disease (AD). Dr. Blum is a Senior Investigator and a Research
Slide 18: MRVL – TSXV MBCOF - OTC
Rod Matheson Dr.MarkWilliams rod@marvelbiosciences.com mark@marvelbiosciences.com 403-770-2468 431-777-7759 MRVL – TSXV MBCOF - OTC 18
Slide 19: Statutory Rights of Action
STATUTORY RIGHTS OF ACTION In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy for rescission or damages, or both, in addition to any other right they may have at law, where an offering memorandum (such as this Presentation) and any amendment to i
Marvel Biosciences — Investor Presentation (December 2024) on 6ix